Skip to main content
Top
Published in: Fibrogenesis & Tissue Repair 1/2010

Open Access 01-12-2010 | Research

Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study

Authors: Giorgos A Margaritopoulos, Katerina M Antoniou, Kostas Karagiannis, Katerina D Samara, Ismini Lasithiotaki, Evi Vassalou, Rena Lymbouridou, Helen Koutala, Nikos M Siafakas

Published in: Fibrogenesis & Tissue Repair | Issue 1/2010

Login to get access

Abstract

Background and aim

Toll-like receptors (TLRs), a key component of innate immunity, have recently been implicated in the pathogenesis of interstitial lung diseases (ILDs). As the involvement of TLRs has not yet been fully elucidated, the aim of the current study was to examine the expression of various TLRs in the bronchoalveolar lavage fluid (BALF) of patients with ILDs.

Patients and Methods

We studied prospectively three groups of patients: (1) one group of 35 patients with fibrotic disorders, 16 with idiopathic pulmonary fibrosis (IPF) and 19 with fibrotic interstitial pneumonias associated with collagen tissue disorders (CTD-IPs); (2) one group of 14 patients with pulmonary sarcoidosis; and (3) 11 normal subjects. We evaluated TLR expression with flow cytometry and mRNA expression with real-time PCR.

Results

An overexpression of TLR-3 mRNA was found in fibrotic disorders (CTD-IPs/IPF) in comparison with sarcoidosis (mean ± SD, 1.104 ± 1.087 versus 0.038 ± 0.03; P = 0.04). Additionally, TLR-3 mRNA was increased in CTD-IPs in comparison with IPF (P = 0.001), sarcoidosis (P = 0.002) and controls (P = 0.05). An upregulation in TLR-7 and -9 mRNA expression was detected in IPF (P = 0.05) and sarcoidosis (P = 0.05), respectively, when compared to controls. A higher percentage of TLR-9-expressing cells was found in BALF of CTD-IPs when compared to IPF (mean ± SD, 36.7 ± 7.06 versus 14.85 ± 3.82; P = 0.025).

Conclusion

We observed distinct profiles of TLR expression in fibrotic and granulomatous disorders. It is likely that they could play a key role in the pathogenesis of these diseases and represent future therapeutic targets.
Appendix
Available only for authorised users
Literature
1.
go back to reference Selman M, Pardo A: The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003, 29: S93-S97.PubMed Selman M, Pardo A: The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003, 29: S93-S97.PubMed
2.
go back to reference Kottmann RM, Hogan CM, Phipps RP, Sime PJ: Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology. 2009, 14: 917-933. 10.1111/j.1440-1843.2009.01624.x.CrossRefPubMed Kottmann RM, Hogan CM, Phipps RP, Sime PJ: Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology. 2009, 14: 917-933. 10.1111/j.1440-1843.2009.01624.x.CrossRefPubMed
3.
go back to reference Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med. 2007, 357: 2153-2165. 10.1056/NEJMra071714.CrossRefPubMed Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med. 2007, 357: 2153-2165. 10.1056/NEJMra071714.CrossRefPubMed
4.
go back to reference Tsan MF, Gao B: Endogenous ligands of Toll-like receptors. J Leukoc Biol. 2004, 76: 514-519. 10.1189/jlb.0304127.CrossRefPubMed Tsan MF, Gao B: Endogenous ligands of Toll-like receptors. J Leukoc Biol. 2004, 76: 514-519. 10.1189/jlb.0304127.CrossRefPubMed
5.
go back to reference Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007, 81: 1-5. 10.1189/jlb.0306164.CrossRefPubMed Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007, 81: 1-5. 10.1189/jlb.0306164.CrossRefPubMed
6.
7.
go back to reference Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol. 2004, 4: 499-511. 10.1038/nri1391.CrossRefPubMed Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol. 2004, 4: 499-511. 10.1038/nri1391.CrossRefPubMed
8.
go back to reference Droemann D, Goldmann T, Branscheid D, Clark R, Dalhoff K, Zabel P, Vollmer E: Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol. 2003, 119: 103-108.PubMed Droemann D, Goldmann T, Branscheid D, Clark R, Dalhoff K, Zabel P, Vollmer E: Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol. 2003, 119: 103-108.PubMed
9.
go back to reference Morris GE, Whyte MK, Martin GF, Jose PJ, Dower SK, Sabroe I: Agonists of toll-like receptors 2 and 4 activate airway smooth muscle via mononuclear leukocytes. Am J Respir Crit Care Med. 2005, 171: 814-822. 10.1164/rccm.200403-406OC.CrossRefPubMed Morris GE, Whyte MK, Martin GF, Jose PJ, Dower SK, Sabroe I: Agonists of toll-like receptors 2 and 4 activate airway smooth muscle via mononuclear leukocytes. Am J Respir Crit Care Med. 2005, 171: 814-822. 10.1164/rccm.200403-406OC.CrossRefPubMed
10.
go back to reference Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O'Neill SJ, McElvaney NG: TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol. 2005, 174: 1638-1646.CrossRefPubMed Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O'Neill SJ, McElvaney NG: TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol. 2005, 174: 1638-1646.CrossRefPubMed
11.
12.
go back to reference Meneghin A, Choi ES, Evanoff HL, Kunkel SL, Martinez FJ, Flaherty KR, Toews GB, Hogaboam CM: TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol. 2008, 130: 979-992. 10.1007/s00418-008-0466-z.CrossRefPubMed Meneghin A, Choi ES, Evanoff HL, Kunkel SL, Martinez FJ, Flaherty KR, Toews GB, Hogaboam CM: TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol. 2008, 130: 979-992. 10.1007/s00418-008-0466-z.CrossRefPubMed
13.
go back to reference Yang HZ, Cui B, Liu HZ, Chen ZR, Yan HM, Hua F, Hu ZW: Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol. 2009, 182: 692-702.CrossRefPubMed Yang HZ, Cui B, Liu HZ, Chen ZR, Yan HM, Hua F, Hu ZW: Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol. 2009, 182: 692-702.CrossRefPubMed
14.
go back to reference Saboor SA, Johnson NM, McFadden J: Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet. 1992, 339: 1012-1015. 10.1016/0140-6736(92)90535-B.CrossRefPubMed Saboor SA, Johnson NM, McFadden J: Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet. 1992, 339: 1012-1015. 10.1016/0140-6736(92)90535-B.CrossRefPubMed
15.
go back to reference Abe C, Iwai K, Mikami R, Hosoda Y: Frequent isolation of Propionibacterium acnes from sarcoidosis lymph nodes. Zentralbl Bakteriol Mikrobiol Hyg A. 1984, 256: 541-547.PubMed Abe C, Iwai K, Mikami R, Hosoda Y: Frequent isolation of Propionibacterium acnes from sarcoidosis lymph nodes. Zentralbl Bakteriol Mikrobiol Hyg A. 1984, 256: 541-547.PubMed
16.
go back to reference Wikén M, Grunewald J, Eklund A, Wahlström J: Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis. J Clin Immunol. 2009, 29: 78-89. 10.1007/s10875-008-9225-0.CrossRefPubMed Wikén M, Grunewald J, Eklund A, Wahlström J: Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis. J Clin Immunol. 2009, 29: 78-89. 10.1007/s10875-008-9225-0.CrossRefPubMed
17.
go back to reference Schürmann M, Kwiatkowski R, Albrecht M, Fischer A, Hampe J, Müller-Quernheim J, Schwinger E, Schreiber S: Study of Toll-like receptor gene loci in sarcoidosis. Clin Exp Immunol. 2008, 152: 423-431. 10.1111/j.1365-2249.2008.03621.x.PubMedCentralCrossRefPubMed Schürmann M, Kwiatkowski R, Albrecht M, Fischer A, Hampe J, Müller-Quernheim J, Schwinger E, Schreiber S: Study of Toll-like receptor gene loci in sarcoidosis. Clin Exp Immunol. 2008, 152: 423-431. 10.1111/j.1365-2249.2008.03621.x.PubMedCentralCrossRefPubMed
18.
go back to reference Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P, Boumpas DT: Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 2006, 54: 3601-3611. 10.1002/art.22197.CrossRefPubMed Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P, Boumpas DT: Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 2006, 54: 3601-3611. 10.1002/art.22197.CrossRefPubMed
19.
go back to reference Brentano F, Schorr O, Gay RE, Gay S, Kyburz D: RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 2005, 52: 2656-2665. 10.1002/art.21273.CrossRefPubMed Brentano F, Schorr O, Gay RE, Gay S, Kyburz D: RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 2005, 52: 2656-2665. 10.1002/art.21273.CrossRefPubMed
20.
go back to reference Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, van den Berg WB, Radstake TR: The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 2005, 52: 2313-2322. 10.1002/art.21278.CrossRefPubMed Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, van den Berg WB, Radstake TR: The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 2005, 52: 2313-2322. 10.1002/art.21278.CrossRefPubMed
21.
go back to reference Kyburz D, Rethage J, Seibl R, Lauener R, Gay RE, Carson DA, Gay S: Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum. 2003, 48: 642-650. 10.1002/art.10848.CrossRefPubMed Kyburz D, Rethage J, Seibl R, Lauener R, Gay RE, Carson DA, Gay S: Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum. 2003, 48: 642-650. 10.1002/art.10848.CrossRefPubMed
22.
23.
go back to reference Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL, Gregersen PK, Behrens TW: Gene expression profiling in human autoimmunity. Immunol Rev. 2006, 210: 120-137. 10.1111/j.0105-2896.2006.00367.x.CrossRefPubMed Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL, Gregersen PK, Behrens TW: Gene expression profiling in human autoimmunity. Immunol Rev. 2006, 210: 120-137. 10.1111/j.0105-2896.2006.00367.x.CrossRefPubMed
24.
go back to reference American Thoracic Society/European Respiratory Society International: Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002, 165: 277-304.CrossRef American Thoracic Society/European Respiratory Society International: Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002, 165: 277-304.CrossRef
25.
go back to reference Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV: Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related. Am J Respir Crit Care Med. 2007, 175: 705-711. 10.1164/rccm.200607-912OC.CrossRefPubMed Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV: Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related. Am J Respir Crit Care Med. 2007, 175: 705-711. 10.1164/rccm.200607-912OC.CrossRefPubMed
26.
go back to reference American Rheumatism Association Diagnostic and Therapeutic Criteria Subcommittee for Scleroderma: Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1988, 23: 581-590. 10.1002/art.1780230510. American Rheumatism Association Diagnostic and Therapeutic Criteria Subcommittee for Scleroderma: Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1988, 23: 581-590. 10.1002/art.1780230510.
27.
go back to reference Arnett FC: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed Arnett FC: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed
28.
go back to reference Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP: ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999, 16: 149-173.PubMed Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP: ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999, 16: 149-173.PubMed
29.
go back to reference Antoniou KM, Tzouvelekis A, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Rachiotis G, Tzanakis N, Bouros D, Milic-Emili J, Siafakas NM: Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest. 2006, 130: 982-988. 10.1378/chest.130.4.982.CrossRefPubMed Antoniou KM, Tzouvelekis A, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Rachiotis G, Tzanakis N, Bouros D, Milic-Emili J, Siafakas NM: Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest. 2006, 130: 982-988. 10.1378/chest.130.4.982.CrossRefPubMed
30.
go back to reference Haslam PL, Baughman RP: Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J. 1999, 14: 245-248. 10.1034/j.1399-3003.1999.14b01.x.CrossRefPubMed Haslam PL, Baughman RP: Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J. 1999, 14: 245-248. 10.1034/j.1399-3003.1999.14b01.x.CrossRefPubMed
31.
go back to reference Soulitzis N, Karyotis I, Delakas D, Spandidos DA: Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol. 2006, 29: 305-314.PubMed Soulitzis N, Karyotis I, Delakas D, Spandidos DA: Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol. 2006, 29: 305-314.PubMed
32.
go back to reference Antoniou KM, Soufla G, Proklou A, Margaritopoulos G, Choulaki C, Lymbouridou R, Samara KD, Spandidos DA, Siafakas NM: Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study. Clin Dev Immunol. 2009, 2009:537929 Antoniou KM, Soufla G, Proklou A, Margaritopoulos G, Choulaki C, Lymbouridou R, Samara KD, Spandidos DA, Siafakas NM: Different activity of the biological axis VEGF-Flt-1 (fms-like tyrosine kinase 1) and CXC chemokines between pulmonary sarcoidosis and idiopathic pulmonary fibrosis: a bronchoalveolar lavage study. Clin Dev Immunol. 2009, 2009:537929
33.
go back to reference Otte JM, Rosenberg IM, Podolsky DK: Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology. 2003, 124: 1866-1878. 10.1016/S0016-5085(03)00403-7.CrossRefPubMed Otte JM, Rosenberg IM, Podolsky DK: Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology. 2003, 124: 1866-1878. 10.1016/S0016-5085(03)00403-7.CrossRefPubMed
34.
go back to reference Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997, 159: 1437-1443.PubMed Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM: The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997, 159: 1437-1443.PubMed
35.
go back to reference Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM: Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J. 2009, 33: 882-896. 10.1183/09031936.00152607.CrossRefPubMed Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM: Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J. 2009, 33: 882-896. 10.1183/09031936.00152607.CrossRefPubMed
36.
go back to reference Margaritopoulos GA, Antoniou KM, Soufla G, Karagiannis K, Proklou A, Lasithiotaki I, Tzanakis N, Spandidos DA, Siafakas NM: Upregulation of stromal cell derived factor-1alpha in collagen vascular diseases-associated interstitial pneumonias (CVDs-IPs). Pulm Pharmacol Ther. 2010, 23: 115-120. 10.1016/j.pupt.2009.10.008.CrossRefPubMed Margaritopoulos GA, Antoniou KM, Soufla G, Karagiannis K, Proklou A, Lasithiotaki I, Tzanakis N, Spandidos DA, Siafakas NM: Upregulation of stromal cell derived factor-1alpha in collagen vascular diseases-associated interstitial pneumonias (CVDs-IPs). Pulm Pharmacol Ther. 2010, 23: 115-120. 10.1016/j.pupt.2009.10.008.CrossRefPubMed
37.
go back to reference Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K: Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax. 2000, 55: 958-961. 10.1136/thorax.55.11.958.PubMedCentralCrossRefPubMed Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K: Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax. 2000, 55: 958-961. 10.1136/thorax.55.11.958.PubMedCentralCrossRefPubMed
38.
go back to reference Yonemaru M, Kasuga I, Kusumoto H, Kunisawa A, Kiyokawa H, Kuwabara S, Ichinose Y, Toyama K: Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur Respir J. 1997, 10: 2040-2045. 10.1183/09031936.97.10092040.CrossRefPubMed Yonemaru M, Kasuga I, Kusumoto H, Kunisawa A, Kiyokawa H, Kuwabara S, Ichinose Y, Toyama K: Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. Eur Respir J. 1997, 10: 2040-2045. 10.1183/09031936.97.10092040.CrossRefPubMed
39.
go back to reference Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, Brigham KL, Oates JA, Loyd JE, Stecenko AA: Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. 2003, 41: 2633-2640. 10.1128/JCM.41.6.2633-2640.2003.PubMedCentralCrossRefPubMed Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, Brigham KL, Oates JA, Loyd JE, Stecenko AA: Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. 2003, 41: 2633-2640. 10.1128/JCM.41.6.2633-2640.2003.PubMedCentralCrossRefPubMed
40.
go back to reference Searle J, Kerr JF, Bishop CJ: Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol Annu. 1982, 17 (Pt 2): 229-259.PubMed Searle J, Kerr JF, Bishop CJ: Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol Annu. 1982, 17 (Pt 2): 229-259.PubMed
41.
go back to reference Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, Nicholson AG, du Bois RM, Wells AU: Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008, 177: 190-194. 10.1164/rccm.200612-1759OC.CrossRefPubMed Antoniou KM, Hansell DM, Rubens MB, Marten K, Desai SR, Siafakas NM, Nicholson AG, du Bois RM, Wells AU: Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008, 177: 190-194. 10.1164/rccm.200612-1759OC.CrossRefPubMed
42.
go back to reference Symvoulakis EK, Zaravinos A, Panutsopulos D, Zoras O, Papalambros E, Sigala F, Spandidos DA: Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. Int J Biol Markers. 2007, 22: 12-18.PubMed Symvoulakis EK, Zaravinos A, Panutsopulos D, Zoras O, Papalambros E, Sigala F, Spandidos DA: Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. Int J Biol Markers. 2007, 22: 12-18.PubMed
43.
go back to reference Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B: Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res. 2005, 6: 68-10.1186/1465-9921-6-68.PubMedCentralCrossRefPubMed Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B: Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res. 2005, 6: 68-10.1186/1465-9921-6-68.PubMedCentralCrossRefPubMed
44.
go back to reference Noakes PS, Hale J, Thomas R, Lane C, Devadason SG, Prescott SL: Maternal smoking is associated with impaired neonatal toll-like-receptor-mediated immune responses. Eur Respir J. 2006, 28: 721-729. 10.1183/09031936.06.00050206.CrossRefPubMed Noakes PS, Hale J, Thomas R, Lane C, Devadason SG, Prescott SL: Maternal smoking is associated with impaired neonatal toll-like-receptor-mediated immune responses. Eur Respir J. 2006, 28: 721-729. 10.1183/09031936.06.00050206.CrossRefPubMed
Metadata
Title
Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study
Authors
Giorgos A Margaritopoulos
Katerina M Antoniou
Kostas Karagiannis
Katerina D Samara
Ismini Lasithiotaki
Evi Vassalou
Rena Lymbouridou
Helen Koutala
Nikos M Siafakas
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Fibrogenesis & Tissue Repair / Issue 1/2010
Electronic ISSN: 1755-1536
DOI
https://doi.org/10.1186/1755-1536-3-20

Other articles of this Issue 1/2010

Fibrogenesis & Tissue Repair 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.